LFWD
Lifeward Ltd.
$6.30
-6.80%
2026-05-08
About Lifeward Ltd.
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
Key Fundamentals
Forward P/E
-5.16
EPS (TTM)
$-17.16
ROE
-146.1%
Revenue Growth (YoY)
-32.7%
Profit Margin
-90.4%
Debt/Equity
52.18
Price/Book
1.18
Beta
0.33
Market Cap
$18.1M
Avg Volume (10D)
5K
Recent Breakout Signals
No recent breakout signals detected for LFWD.
Recent Price Range (60 Days)
60D High
$7.69
60D Low
$4.14
Avg Volume
16K
Latest Close
$6.30
Get breakout alerts for LFWD
Sign up for Breakout Scanner to receive daily notifications when LFWD triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Lifeward Ltd. (LFWD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors LFWD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. LFWD operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.